Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain
INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance